Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04962178

Evaluate Early Invasive Strategy for Patients With STEMI Presenting 24-48 Hours From Symptom Onset

ST-segment Elevation Myocardial Infarction (STEMI) Clinical Trial

Official title:
A Randomized Multicenter Trial to Evaluate Early Invasive Strategy for Patients With Acute ST-segment Elevation Myocardial Infarction Presenting 24-48 Hours From Symptom Onset

Clinical Trial Summary

The primary objective of the trial is to evaluate the efficacy of early invasive strategy for STEMI patients within 24-48h of symptom onset.

Clinical Trial Description

At present, timely primary percutaneous coronary intervention (PCI) is the preferred strategy for ST-segment elevation myocardial infarction (STEMI) patients within 24h of symptom onset. In stable STEMI patients presenting 12 to 48 hours from symptom onset, BRAVE-2 Trial (n = 365) showed improved myocardial salvage and 4-year survival in patients treated with primary PCI compared with conservative treatment alone. However, data is scarce about the reperfusion strategy focusing on STEMI patients within 24-48h of symptom onset. Further investigations are warranted to explore the best timing of invasive strategy for STEMI patients within 24-48h of symptom onset. Given that no randomized clinical trial is designed especially for STEMI patients within 24-48h of symptom onset, and limited data is available to evaluate the efficacy of early invasive strategy for the special subgroup of STEMI patients, investigators plan to perform a controlled, randomized trial to evaluate the efficacy of early invasive strategy for STEMI patients within 24-48h of symptom onset. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04962178
Study type Interventional
Source Shanghai Zhongshan Hospital
Contact Xin Zhong, MD
Phone +86 13585678706
Email zhong.xin@zs-hospital.sh.cn
Status Recruiting
Phase N/A
Start date September 9, 2021
Completion date June 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04549766 - Predictive Value of PRECISE DAPT Score in STEMI Patients After Primary PCI
Not yet recruiting NCT05511831 - The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI Phase 4
Completed NCT05649696 - Prolonged Clinical Follow-up of OPTIMA-5 Phase 4
Recruiting NCT05506449 - The RECOVER IV Trial N/A
Completed NCT01144819 - Platelet Inhibition in the Acute Phase of STEMI N/A
Recruiting NCT03539133 - Systemic Organ Communication in STEMI
Completed NCT01642667 - Pharmacoinvasive Therapy With Prourokinase Phase 2/Phase 3
Completed NCT04131816 - HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program N/A
Recruiting NCT03768453 - EARLY-MYO-CMR Registry
Completed NCT04942977 - Rehabilitation After Acute Coronary Syndrome: a New Telemonitoring Strategy N/A
Recruiting NCT04912518 - Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction N/A
Completed NCT04996901 - The Chinese STEMI PPCI Registry (CSPR)
Recruiting NCT05892042 - Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction N/A
Completed NCT02197117 - Effect of Remote Ischemic Conditioning in Heart Attack Patients N/A
Completed NCT02733341 - The Effect of IV Cangrelor and Oral Ticagrelor Study Phase 4
Not yet recruiting NCT04110691 - Impact of Stent Length and Diameter on Patients Undergoing Primary PCI
Recruiting NCT05510661 - Use of Export in Primary Percutaneous Coronary Intervention N/A
Recruiting NCT05709626 - PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction Phase 4
Recruiting NCT05046483 - Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
Active, not recruiting NCT04828681 - Angio-IMR and Cardiac MR-derived MVO in STEMI Patients